Open Access
| Issue |
Med Sci (Paris)
Volume 41, Number 10, Octobre 2025
|
|
|---|---|---|
| Page(s) | 720 - 723 | |
| Section | Nouvelles | |
| DOI | https://doi.org/10.1051/medsci/2025155 | |
| Published online | 19 November 2025 | |
- Schadendorf D, Akkooi ACJ van, Berking C, et al. Melanoma. Lancet 2018 ; 392 : 971–84. [Google Scholar]
- Kozar I, Margue C, Rothengatter S, et al. Many ways to resistance: How melanoma cells evade targeted therapies. Biochim Biophys Acta Rev Cancer 2019 ; 1871 : 313–22. [Google Scholar]
- Wouters J, Kalender-Atak Z, Minnoye L, et al. Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. Nat Cell Biol 2020 ; 22 : 986–98. [Google Scholar]
- Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell 2017 ; 168 : 629–43. [Google Scholar]
- Berico P, Nogaret M, Cigrang M, et al. Super-enhancer-driven expression of BAHCC1 promotes melanoma cell proliferation and genome stability. Cell Rep 2023 ; 42 : 113363. [Google Scholar]
- Eliades P, Abraham BJ, Ji Z, et al. High MITF expression is associated with super-enhancers and suppressed by CDK7 inhibition in melanoma. J Invest Dermatol 2018 ; 138 : 1582–90. [Google Scholar]
- Berico P, Cigrang M, Davidson G, et al. CDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma. EMBO Rep 2021 ; 22 : e51683. [Google Scholar]
- Donati B, Lorenzini E, Ciarrocchi A. BRD4 and cancer: going beyond transcriptional regulation. Mol Cancer 2018 ; 17 : 164. [Google Scholar]
- Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020 ; 21 : 645–54. [Google Scholar]
- Costanzo F, Martínez Diez M, Santamaría Nuñez G, et al. Promoters of ASCL1-and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells. EMBO Mol Med 2022 ; 14 : e14841. [Google Scholar]
- Santamaría Nuñez G, Robles CMG, Giraudon C, et al. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther 2016 ; 15 : 2399–412. [Google Scholar]
- Yu Z, Spiegel J, Melidis L, et al. Chem-map profiles drug binding to chromatin in cells. Nat Biotechnol 2023 ; 41 : 1265–71. [Google Scholar]
- Cigrang M, Obid J, Nogaret M, et al. Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. Nat Commun 2025 ; 16 : 512. [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.